| Objective: To retrospectively analyze the clinical efficacy and safety of Huaganxian prescription in the treatment of chronic hepatitis B hepatic fibrosis,and to compare the efficacy difference between Huaganxian prescription and Fuzheng Huayu capsule,in order to provide reference for the treatment of antiliver fibrosis.Methods: Patients with chronic hepatitis B and hepatic fibrosis who first visited the Department of Liver Diseases of the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine from June 2018 to June2021 and met the inclusion criteria were retrospectively collected.According to different means of intervention to patients classified as A,B,C three groups,each group were collected with 40 cases so far,A set of antiviral treatment for simple entecavir dispersible tablet,group B for the centralizer blood capsule treatment,joint entecavir dispersible tablet group C for chemical liver fiber treatment,joint entecavir dispersible tablet and meet the course more than six months.There were collected and compared and analyzed in each group at the beginning of treatment and 6 months after treatment for liver function(ALT,AST),chitinase-3-like protein 1(CHI3L1),four items of liver fibrosis(HA,PCⅢ,Ⅳ-C,LN),HBV-DNA changes,liver stiffness measurement(LSM),TCM symptom score and efficacy results,and the safety of the treatment were evaluated.Results: 1.Liver function and CHI3L1: After 6 months of treatment,the levels of ALT,AST and CHI3L1 in each group were significantly lower than those before treatment(P<0.05),and the improvement of ALT,AST and CHI3L1 in the group C was better than that in the A and B of control group,with statistical significance(P<0.05).2.Indexes of liver fibrosis: After 6 months of treatment,the indexes of HA,PCⅢ,Ⅳ-C,LN and LSM in each group were significantly decreased compared with those before treatment(P<0.05),and the indexes of liver fibrosis in the group C were most significantly decreased.HA,PCⅢ,Ⅳ-C,LN and LSM were compared between the group C and group A,and the differences were statistically significant(P<0.05).After treatment,HA,PCⅢ and LSM of the group C were compared with group B,and the differences were statistically significant(P<0.05).However,there was no significant difference in Ⅳ-C and LN between the group C and group B after treatment(P > 0.05).3.HBV-DNA changes: After 6 months of treatment,the patients with negative cases and overcast rate were significantly increased(P < 0.05),but the difference is compared between three groups has no statistical significance(P >0.05).4.TCM symptom score: After 6 months of treatment,the TCM symptom score of each group decreased significantly(P<0.05),and the decline of TCM symptom score of the group C was better than that of the other groups,with statistical significance(P<0.05).5.TCM syndrome efficacy: After 6 months of treatment,the total effective rate of TCM syndrome in group A,B and C was 77.5%,85.0% and 95.0%,respectively.There was statistically significant difference in TCM syndrome efficacy between group C and group A(P=0.002<0.05),but there was no statistically significant difference between group C and group B,between group A and group B(P > 0.05).Conclusion(s): 1.Huaganxian prescription has significant clinical efficacy in the treatment of chronic hepatitis B liver fibrosis patients,which can improve liver function transaminase,CHI3L1 and liver fibrosis index levels,and can cooperate with entecavir to control HBV-DNA replication,effectively relieve liver inflammation and delay the progression of liver fibrosis.2.Huaganxian prescription can reduce TCM syndrome score,improve TCM symptoms,improve clinical efficacy,and has good safety. |
PDF Full Text Request